Milestone Pharmaceuticals Inc. (MIST)
Healthcare · NMS
Fundamentals
Valuation and ratings
Milestone Pharmaceuticals Inc. trades at USD1.16, which is 59% above the USD0.48 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 25 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
MIST earnings and analyst estimates
Recommendation mix, 6 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
MIST passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Two Sigma, TWO SIGMA INVESTMENTS, LP$2.76M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$2.31M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$1.84M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$1.29M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$234.1K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Milestone Pharmaceuticals Inc. (MIST) undervalued?
Against our discounted cash flow estimate of USD0.48, MIST at USD1.16 is 59% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own MIST?
5 of the institutions we track reported a position in MIST in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does MIST report earnings next?
Milestone Pharmaceuticals Inc. is scheduled to report on 12 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for MIST, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.